Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib maintenance in mCRPC with HRR gene alterations after docetaxel
2021-001205-73Phase 2Completed
- Sponsor
- IMPACT Therapeutics
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Senaparib maintenance with Placebo maintenance (2 arms). Started May 2021; status: completed.
02
Drugs
senaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2021-001205-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001205-73.